The relationship between tissue factor and cancer progression: Insights from bench and bedside

Blood

Volumn 119, Issue 4, 2012, Pages 924-932

  Van Den Berg, Yascha W ^a   Osanto, Susanne ^a   Reitsma, Pieter H ^a   Versteeg, Henri H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALT 836; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 7A; GEMCITABINE; PCI 27483; PROTEINASE ACTIVATED RECEPTOR 2; THROMBOPLASTIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

BREAST CANCER; CANCER GROWTH; DIGESTIVE SYSTEM CANCER; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UROGENITAL TRACT CANCER;

EID: 84856283500     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-317685     Document Type: Review

References (99)

1. Versteeg HH, Peppelenbosch MP, Spek CA. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling? Thromb Haemost. 2001;86(6):1353-1359. (Pubitemid 34007503)
2. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996;2(2): 209-215. (Pubitemid 26054985)
3. Rak J. Microparticles in cancer. Semin Thromb Hemost. 2010;36(8):888-906.
4. Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost. 2006;32(1):24-32.
5. van den BergYW, van den Hengel LG, Myers HR, et al. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci U S A. 2009;106(46):19497-19502.
6. Hobbs JE, Zakarija A, Cundiff DL, et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res. 2007;120(suppl 2): S13-S21. (Pubitemid 350101769)
7. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105(4):1734-1741. (Pubitemid 40223697)
8. Rao B, Gao Y, Huang J, et al. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis. Int J Colorectal Dis. 2011;26(5):593-601.
9. Rong Y, Belozerov VE, Tucker-Burden C, et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009;69(6):2540-2549.
10. Kato S, Pinto M, Carvajal A, et al. Tissue factor is regulated by epidermal growth factor in normal and malignant human endometrial epithelial cells. Thromb Haemost. 2005;94(2):444-453. (Pubitemid 41122502)
11. Milsom CC, Yu JL, Mackman N, et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res. 2008;68(24):10068-10076.
12. Provencal M, Berger-Thibault N, Labbe D, et al. Tissue factor mediates the HGF/Met-induced antiapoptotic pathway in DAOY medulloblastoma cells. J Neurooncol. 2010;97(3):365-372.
13. Regina S, Valentin JB, Lachot S, et al. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem. 2009;55(10):1834-1842.
14. Regina S, Rollin J, Blechet C, et al. Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J Thorac Oncol. 2008;3(7):689-697.
15. Vrana JA, Stang MT, Grande JP, Getz MJ. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res. 1996;56(21):5063-5070. (Pubitemid 26374450)
16. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010;468(7325):829-833.
17. Milsom C, Anderson GM, Weitz JI, Rak J. Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost. 2007;5(12):2550-2552. (Pubitemid 350154368)
18. Rong Y, Post DE, Pieper RO, et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 2005;65(4):1406-1413. (Pubitemid 40270169)
19. Rong Y, Hu F, Huang R, et al. Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res. 2006;66(14): 7067-7074. (Pubitemid 44197683)
20. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A. 1990;87(18):6934-6938.
21. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, et al. PAR3 is a cofactor for PAR4 activation by thrombin. Nature. 2000;404(6778):609-613. (Pubitemid 30205059)
22. Ostrowska E, Reiser G. The protease-activated receptor-3 (PAR-3) can signal autonomously to induce interleukin-8 release. Cell Mol Life Sci. 2008;65(6):970-981.
23. Liu Y, Mueller BM. Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. Biochem Biophys Res Commun. 2006; 344(4):1263-1270.
24. Hjortoe GM, Petersen LC, Albrektsen T, et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004;103(8):3029-3037. (Pubitemid 38451676)
25. Albrektsen T, Sorensen BB, Hjorto GM, et al. Transcriptional program induced by factor VIIatissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost. 2007;5(8):1588-1597. (Pubitemid 47091396)
26. Ott I, Weigand B, Michl R, et al. Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation. 2005; 111(3):349-355. (Pubitemid 40165343)
27. Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med. 2004;10(5):502-509. (Pubitemid 38667909)
28. Dorfleutner A, Hintermann E, Tarui T, Takada Y, Ruf W. Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell. 2004; 15(10):4416-4425. (Pubitemid 39299092)
29. Dorfleutner A, Ruf W. Regulation of tissue factor cytoplasmic domain phosphorylation by palmitoylation. Blood. 2003;102(12):3998-4005. (Pubitemid 37486981)
30. Versteeg HH, Schaffner F, Kerver M, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008;111(1):190-199.
31. Schaffner F, Versteeg HH, Schillert A, et al. Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood. 2010;116(26):6106-6113.
32. Koizume S, Jin MS, Miyagi E, et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res. 2006;66(19):9453-9460. (Pubitemid 44623642)
33. Koizume S, Yokota N, Miyagi E, et al. Hepatocyte nuclear factor-4-independent synthesis of coagulation factor VII in breast cancer cells and its inhibition by targeting selective histone acetyltransferases. Mol Cancer Res. 2009;7(12):1928-1936.
34. Yokota N, Koizume S, Miyagi E, et al. Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer. 2009;101(12):2023-2029.
35. Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood. 2010;116(5):815-818.
36. Guo W, Wang H, Zhao W, et al. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells. Chin Med J. 2001;114(1):30-34. (Pubitemid 33636547)
37. Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 2003;9(4):458-462. (Pubitemid 36460081)
38. van den Berg YW, Versteeg HH. Alternatively spliced tissue factor: a crippled protein in coagulation or a key player in non-haemostatic processes? Hämostaseologie. 2010;30(3):144-149.
39. Rollin J, Regina S, Gruel Y. Tumour expression of alternatively spliced tissue factor is a prognostic marker in non-small cell lung cancer. J Thromb Haemost. 2010;8(3):607-610.
40. Goldin-Lang P, Tran QV, Fichtner I, et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep. 2008;20(1):123-128.
41. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994;94(3):1320-1327. (Pubitemid 24286478)
42. Hembrough TA, Swartz GM, Papathanassiu A, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 2003;63(11): 2997-3000. (Pubitemid 36667175)
43. Versteeg HH, Schaffner F, Kerver M, et al. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res. 2008;68(17):7219-7227.
44. Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A. 1999;96(15):8663-8668. (Pubitemid 29354848)
45. Yu J, May L, Milsom C, et al. Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol. 2008;28(11):1975- 1981.
46. Palumbo JS, Talmage KE, Massari JV, et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007; 110(1):133-141. (Pubitemid 47026828)
47. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A. 1992;89(24):11832-11836. (Pubitemid 23004738)
48. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A. 1995;92(18):8205-8209.
49. Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest. 1998;101(7):1372-1378. (Pubitemid 28166834)
50. Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost. 2006;32(suppl 1):61-68.
51. Horowitz NA, Blevins EA, Miller WM, et al. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood. 2011;118(10):2889-2895.
52. Camerer E, Qazi AA, Duong DN, et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004;104(2): 397-401. (Pubitemid 38900020)
53. Sturm U, Luther T, Albrecht S, et al. Immunohistological detection of tissue factor in normal and abnormal human mammary glands using monoclonal antibodies. Virchows Arch A Pathol Anat Histopathol. 1992;421(2):79-86.
54. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer. 2000;83(2): 164-170. (Pubitemid 30411712)
55. Ryden L, Grabau D, Schaffner F, et al. Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int J Cancer. 2010;126(10):2330- 2340.
56. Sawada M, Miyake S, Ohdama S, et al. Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer. 1999;79(3):472-477. (Pubitemid 29046221)
57. De Meis E, Azambuja D, Ayres-Silva JP, et al. Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma. Braz J Med Biol Res. 2010;43(4):403-408.
58. Ribeiro FS, Simao TA, Amoedo ND, et al. Evidence for increased expression of tissue factor and protease-activated receptor-1 in human esophageal cancer. Oncol Rep. 2009;21(6):1599-1604.
59. Chen L, Luo G, Tan Y, et al. Immunolocalisation of tissue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient. Acta Histochem. 2010;112(3):233-239.
60. Yamashita H, Kitayama J, Ishikawa M, Nagawa H. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol. 2007;95(4):324-331. (Pubitemid 46355509)
61. Poon RT, Lau CP, Ho JW, et al. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res. 2003;9(14):5339-5345. (Pubitemid 37413589)
62. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg. 1995;82(8):1101-1104.
63. Nitori N, Ino Y, Nakanishi Y, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2005;11(7): 2531-2539. (Pubitemid 40569450)
64. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007; 13(10):2870-2875. (Pubitemid 46849560)
65. Shigemori C, Wada H, Matsumoto K, et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost. 1998;80(6):894-898. (Pubitemid 28556688)
66. Nakasaki T, Wada H, Shigemori C, et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol. 2002;69(4): 247-254. (Pubitemid 34259846)
67. Seto S, Onodera H, Kaido T, et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer. 2000;88(2):295-301. (Pubitemid 30051812)
68. Altomare DF, Rotelli MT, Pentimone A, et al. Tissue factor and vascular endothelial growth factor expression in colorectal cancer: relation with cancer recurrence. Colorectal Dis. 2007;9(2):133-138. (Pubitemid 46111596)
69. Forster Y, Meye A, Albrecht S, et al. Tissue specific expression and serum levels of human tissue factor in patients with urological cancer. Cancer Lett. 2003;193(1):65-73. (Pubitemid 36416613)
70. Maciel EO, Carvalhal GF, da Silva VD, Batista EL Jr, Garicochea B. Increased tissue factor expression and poor nephroblastoma prognosis. J Urol. 2009;182(4):1594-1599.
71. Abdulkadir SA, Carvalhal GF, Kaleem Z, et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol. 2000; 31(4):443-447. (Pubitemid 30262866)
72. Akashi T, Furuya Y, Ohta S, Fuse H. Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology. 2003;62(6):1078-1082. (Pubitemid 37510095)
73. Yao JL, Ryan CK, Francis CW, et al. Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest. 2009; 27(4):430-434.
74. Kaushal V, Mukunyadzi P, Siegel ER, et al. Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol. 2008;16(1):1-6.
75. Patry G, Hovington H, Larue H, et al. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscleinvasive bladder cancer. Int J Cancer. 2008; 122(7):1592-1597. (Pubitemid 351294968)
76. Depasquale I, Thompson WD. Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF. Histopathology. 2008;52(4):500-509. (Pubitemid 351327988)
77. Kageshita T, Funasaka Y, Ichihashi M, et al. Tissue factor expression and serum level in patients with melanoma does not correlate with disease progression. Pigment Cell Res. 2001;14(3):195-200. (Pubitemid 32931058)
78. Hamada K, Kuratsu J, Saitoh Y, et al. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer. 1996;77(9): 1877-1883. (Pubitemid 26125190)
79. Guan M, Jin J, Su B, Liu WW, Lu Y. Tissue factor expression and angiogenesis in human glioma. Clin Biochem. 2002;35(4):321-325. (Pubitemid 34804904)
80. Rollin J, Regina S, Gruel Y. Tumor expression of alternatively spliced tissue factor is a prognostic marker in non-small cell lung cancer. J Thromb Haemost. 2010;8(3):607-610.
81. Kageshita T, Funasaka Y, Ichihashi M, et al. Differential expression of tissue factor and tissue factor pathway inhibitor in metastatic melanoma lesions. Pigment Cell Res. 2002;15(3):212-216. (Pubitemid 34608979)
82. Bledsoe JG, Slack SM. Tissue factor expression by rat osteosarcoma cells adherent to tissue culture polystyrene and selected orthopedic biomaterials. J Biomater Sci Polym Ed. 1998;9(12): 1305-1312. (Pubitemid 28525930)
83. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6): 715-722. (Pubitemid 40216041)
84. Negaard HF, Iversen PO, Ostenstad B, et al. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor. Thromb Haemost. 2008;99(6):1040-1048. (Pubitemid 351810485)
85. Negaard HF, Iversen N, Bowitz-Lothe IM, et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia. 2009;23(1):162-169.
86. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: duration of anticoagulation trial. N Engl J Med. 2000;342(26):1953-1958. (Pubitemid 30419090)
87. Pengo V, Noventa F, Denas G, et al. Long-term use of vitamin K antagonists and incidence of cancer: a population-based study. Blood. 2011; 117(5):1707-1709.
88. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med. 2004;351(17):1772-1777.
89. Love TE. Safety study of recombinant NAPc2 to prevent tumor progression and metastases in metastatic colon cancer (www.clinicaltrials. gov; Bethesda, MD: National Library of Medicine). http://clinicaltrials.gov/ct2/show/study/ NCT00443573?term=NAPC2&rank=1. Accessed September 14, 2011.
90. Wong HC. A study of ALT-836 in combination with gemcitabine for locally advanced or metastatic solid tumors (www.clinicaltrials.gov; Bethesda, MD: National Library of Medicine). http://clinical trials.gov/ct2/show/study/ NCT01325558. Accessed September 14, 2011.
91. Hedrick E. Study of safety and tolerability of PCI-27483 in patients with pancreatic cancer patients receiving treatment with gemcitabine (www. clinicaltrials.gov; Bethesda, MD: National Library of Medicine). http://clinicaltrials.gov/ct2/show/study/NCT01020006?term=pharmacyclics& rank=1. Accessed September 14, 2011.
92. Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci U S A. 2001;98(21): 12180-12185. (Pubitemid 32959847)
93. Cocco E, Hu Z, Richter CE, et al. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer. 2010;103(6):812-819.
94. Hu Z, Li J. Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer. BMC Immunol. 2010;11:49.
95. Hu Z, Rao B, Chen S, Duanmu J. Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice. BMC Cancer. 2010;10:235.
96. Hu Z, Rao B, Chen S, Duanmu J. Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer. Breast Cancer Res Treat. 2011; 126(3):589-600.
97. Duanmu J, Cheng J, Xu J, Booth CJ, Hu Z. Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy. Br J Cancer. 2011;104(9):1401-1409.
98. Kessler T, Bieker R, Padro T, et al. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res. 2005;11(17):6317-6324. (Pubitemid 41262963)
99. Bieker R, Kessler T, Schwoppe C, et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and firstin-man experience. Blood. 2009;113(20):5019-5027.